Melane Sampson, Author at BioTuesdays

Feature

Astrocyte delivering first-in-class approach to brain injury neuroprotection

Closely held Astrocyte Pharmaceuticals is developing a new category of neuroprotective therapies aimed at reducing early brain damage following stroke, concussion, and traumatic brain injury (TBI). By harnessing the...

February 3, 2026

Executive Moves

STAAR appoints Warren Foust and Deborah Andrews as interim co-CEOs

STAAR Surgical (NASDAQ: STAA) has announced that its board of directors has appointed Warren Foust, president and CEO, and Deborah Andrews, CFO, as interim co-CEOs, effective yesterday. According to STAAR, the board’s...

February 2, 2026

Developments

USPTO grants Acurx Pharmaceuticals patent for DNA Polymerase IIIC inhibitors

Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the U.S. Patent and Trademark Office (USPTO) covering DNA Polymerase IIIC inhibitors including compositions of matter, methods of use, and...

February 2, 2026

Developments

Publication supports scientific rationale for Palvella’s QTORIN in DSAP

Palvella Therapeutics (NASDAQ: PVLA) announced that Clinical and Experimental Dermatology has published a peer-reviewed systematic review synthesizing clinical evidence on off-label topical statin use in porokeratosis...

February 2, 2026

Developments

Kazia reveals compelling data on nuclear PD-L1 degrader NDL2

Kazia Therapeutics (NASDAQ: KZIA) has announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader designed to selectively eliminate nuclear...

January 30, 2026

Executive Moves

Carisa Schultz joins Nuwellis as CFO

Nuwellis (NASDAQ: NUWE) has announced the appointment of Carisa Schultz as chief financial officer (CFO), effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership...

January 30, 2026

Developments

Immunotherapy review highlights Faron’s bexmarilimab in immune-resistant cancer

Faron Pharmaceuticals (AIM: FARN; First North: FARON) has announced the publication of a comprehensive review article in the peer-reviewed journal Immunotherapy detailing the potential of the company’s lead candidate...

January 29, 2026

Developments

OSE expands lusvertikimab into new immune-mediated indications

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has announced that it has selected chronic pouchitis and hidradenitis suppurativa (HS) as new key indications for lusvertikimab, a potential first-in-class IL-7R...

January 29, 2026

Executive Moves

AIML names Dr. Paul Dorian MIA and head of medical advisory board

AIML Innovations (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) has announced the appointment of Paul Dorian, MD, MSc, as its medical innovation architect (MIA) and head of the company’s medical advisory board, effective...

January 28, 2026

Executive Moves

Rani appoints Dr. Alireza Javadi as CTO

Rani Therapeutics (NASDAQ: RANI) has announced the promotion of Alireza Javadi, PhD, to chief technical officer. Prior to the promotion to CTO, Dr. Javadi served as Rani’s VP, technical operations, where he was...

January 28, 2026

Author - Melane Sampson

Astrocyte delivering first-in-class approach to brain injury neuroprotection

STAAR appoints Warren Foust and Deborah Andrews as interim co-CEOs

USPTO grants Acurx Pharmaceuticals patent for DNA Polymerase IIIC inhibitors

Publication supports scientific rationale for Palvella’s QTORIN in DSAP

Kazia reveals compelling data on nuclear PD-L1 degrader NDL2

Carisa Schultz joins Nuwellis as CFO

Immunotherapy review highlights Faron’s bexmarilimab in immune-resistant cancer

OSE expands lusvertikimab into new immune-mediated indications

AIML names Dr. Paul Dorian MIA and head of medical advisory board

Rani appoints Dr. Alireza Javadi as CTO

Subscribe